PTJ
ACAD icon

Paul Tudor Jones’s Acadia Pharmaceuticals ACAD Stock Holding History

Paul Tudor Jones’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,700
Closed -$250K – 3428
2025
Q3 		$250K Buy
+11,700
New +$277K ﹤0.01% 3092

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Paul Tudor Jones's ACAD Position: Q2 2025 in Review

Paul Tudor Jones sold out of Acadia Pharmaceuticals (ACAD) in Q2 2025, closing a stake of 58,640 shares — an estimated $974K sold.

Paul Tudor Jones first reported a position in ACAD in Q3 2014 and held it in 22 quarters. The position peaked at $4.87M in Q3 2019. 311 funds tracked by Wall St. Rank hold ACAD as of Q2 2025.

  • Paul Tudor Jones reported no remaining Acadia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 58,640 Acadia Pharmaceuticals shares in Q2 2025, an estimated $974K.
  • Paul Tudor Jones first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 22 quarters.
  • Paul Tudor Jones's Acadia Pharmaceuticals position peaked at $4.87M in Q3 2019.
  • 311 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2025.

Based on Tudor Investment Corp's 13F filing for Q2 2025, filed 14 Aug 2025.